LBRX · Lb Pharmaceuticals Inc
$39.00
+4.06 (+11.62%)
At close · Jul 29
Market Cap
$1.00B
Shares
28.68M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$39.00
Open$35.14
Day$35.14–39.26
52W$13.36–39.26
Avg vol 30d363K
Short int4.3M · 14.9% float · 17.6d
Short vol62%
DataSep 2025–Jul 2026
Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+59%
above
Price vs 50-day avg
+26%
above
RSI (14)
73
overbought
MACD trend
Positive
52-week position
99%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+20%
trailing
6-month return
+84%
trailing
YTD return
+75%
this year
Relative strength
+78%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
9 of 76 funds reported for Jun 30 · net +154.1K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.86% of float · ▼ -6.4% MoM · 17.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Squeeze score
85
high risk · 0–100
Fundamentals
EPS growth
+98%
Y/Y
Free cash flow
$-35.3M
Balance sheet
$250.2M
net cash
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+59%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
73
Bearish
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $31 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
9 of 76 funds reported for Jun 30 · net +154.1K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
14.86% of float · ▼ -6.4% MoM · 17.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
76 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $13
Now $39 · 99%
52-wk high $39
vs 200-day avg +59%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LBRX
this stock
Lb Pharmaceuticals Inc
|
$1.00B | +75.2% | — | — | 14.9% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LBRX | +8.8% | +20.2% | +84.2% | +20.2% | +75.2% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +11.2% | +22.5% | +77.9% | +22.5% | +68.2% |
Key facts
CIK
1691082
CUSIP
50180M108
13F (30d)
11 filings
11 filers
Visit website
Investor relations